Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.55 |
| ▸ | PGR | P06401 | 7/20 | 0.55 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.55 |
| ▸ | AR | P10275 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14641397 | 0.86 | NR3C1 (0.55) | NR3C1PGRNR3C2AR | |
| SCHEMBL4621610 | 0.86 | NR3C1 (0.73) | NR3C1PGRNR3C2AR | |
| SCHEMBL5645477 | 0.84 | NR3C1 (0.51) | NR3C1PGRNR3C2AR | |
| SCHEMBL6076827 | 0.83 | NR3C1 (0.78) | NR3C1PGRNR3C2AR | |
| SCHEMBL4620586 | 0.82 | NR3C1 (0.51) | NR3C1PGRNR3C2AR | |
| SCHEMBL5642843 | 0.80 | NR3C1 (0.48) | NR3C1PGRNR3C2AR | |
| SCHEMBL4002508 | 0.80 | NR3C1 (0.65) | NR3C1PGRNR3C2AR | |
| SCHEMBL5643383 | 0.79 | NR3C1 (0.53) | NR3C1PGRNR3C2AR | |
| SCHEMBL14604850 | 0.79 | NR3C1 (0.55) | NR3C1PGRNR3C2AR | |
| SCHEMBL4278672 | 0.79 | NR3C1 (0.52) | NR3C1PGRNR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902049-A2 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | disclosed |
| US-20070010514-A1 | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010514-A1 | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010514-A1 | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-11 | — | — | US | disclosed |
| WO-2006136461-A2 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
| US-7112584-B2 | Nonsteroidal antiinflammatory agents | SCHERING AG (DE) | 2006-09-26 | — | — | US | disclosed |
| EP-1572671-A1 | NON-STEROIDAL ANTI-INFLAMMATORY AGENTS | Schering Aktiengesellschaft (DE) | 2005-09-14 | — | — | EP | disclosed |
| US-20040209875-A1 | Nonsteroidal antiinflammatory agents | SCHERIN AKTIENGESELLSCHAFT (DE) | 2004-10-21 | — | — | US | disclosed |
| WO-2004058733-A1 | NON-STEROIDAL ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010514-A1 | Non-steroidal progesterone receptor modulators | PGR, PGRMC1, CYP19A1 | NR3C1 69/4885PGR 1/4885NR3C2 37/4885 |
| US-20040209875-A1 | Nonsteroidal antiinflammatory agents | PTGS1, PTGER1, PTGES | NR3C1 90/4885PGR 648/4885NR3C2 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.